30 closest matches · ranked by relevance
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Squamous Cell Carcinoma of the Head and Neck · Nasopharyngeal Carcinoma · Salivary Gland Cancer
Primary: Local Control Rate — 1; 5 Participants
Head and Neck Squamous Cell Carcinoma
Primary: Major Pathologic Response — 22 Participants
Head and Neck Cancer
Primary: Two-Year Progression Free Survival (PFS) Probability, the Percentage of Patients Estimated to be Alive Without Worsening of Their Disease Two Years After Beginning…
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Squamous Cell Carcinoma of the Head and Neck
Primary: Percentage of Participants With Pathologic Complete Response (pCR) as Determined by Local Pathologic Review — 16.7; 50.0 percentage of participants
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Primary: Progression Free Survival (PFS) During the First-line Treatment Phase — 6.9; 5.5 Months — p=0.051
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
Lip and Oral Cavity Squamous Cell Carcinoma · Oral Cavity Verrucous Carcinoma · Precancerous Condition
Primary: Comparison Between Treatment Groups of the Within-patient Change in MVD Score Following Treatment Initiation
Head and Neck Cancer
Primary: Patient Response to Treatment Measured by RECIST Criteria — 1; 18; 19; 2 participants
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Squamous Cell Carcinoma of the Hypopharynx
Primary: Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria — 6.7; 0 percentage of participants
Head and Neck Cancer
Primary: Overall Response Rate — 0 patients
Head and Neck Cancer
Primary: Progression-free Survival (PFS) Rate — 50; 43; 110; 117 Participants — p=0.83
Head and Neck Cancer · Cancer of the Pharynx · Cancer of the Larynx
Primary: Llocoregional Recurrence — 27 Participants
Head and Neck Cancer
Primary: Overall Survival — 73; 78 percent of patients
Head and Neck Cancer
Primary: Response Probability (Confirmed Complete and Partial Responses) — 0; 2; 38 participants
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma
Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response
Head and Neck Squamous Cell Carcinoma · Squamous Cell Carcinoma of the Head and Neck (SCCHN) · Head and Neck Cancer
Primary: Detection of Malignancy in Excised Lymph Nodes by Pathology or Labeling With Lymphoseek and/or Panitumumab-IRDye800 — 10; 5; 3; NA Lymph nodes
Head and Neck Cancer
Primary: Overall Response — 28 Participants
Oropharyngeal Squamous Cell Cancer
Primary: Median Change in Quality of Life (QOL) From Baseline to 12 Months Post Treatment — -4.2; 0; 6.3; 10.7 score on a scale
Squamous Cell Carcinoma of the Head and Neck · Carcinoma of the Head and Neck
Primary: Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling — 0; 4; 0; 0 Lymph Nodes
Head and Neck Cancer
Primary: Duration of Local Control — 4.6 number of months to local failure
Cancer of Head and Neck · Head and Neck Cancer · Neoplasms, Head and Neck
Primary: Locoregional Recurrence Rates in Cohorts 1 and 2 — 2; 2 Participants
Recurrent Head and Neck Squamous Cell Carcinoma
Primary: Number of Participants With Progression-Free Survival (PFS) — 27 Participants
Head and Neck Cancer
Primary: Overall Survival (Percentage of Participants Alive) — 64.3; 70.3 percentage of patients — p=0.180
Head and Neck Cancer
Primary: Percentage of Patients With Grade 3 and 4 Adverse Events of Nivolumab — 17 Participants
Head and Neck Cancer · Squamous Cell Cancer
Primary: Participant Response Rate — 7 Participants